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The overall aim of this work was to characterize the major angiotensin converting 4 
enzyme (ACE) inhibitory peptides produced by enzymatic hydrolysis of whey 5 
proteins, through the application of a novel integrative process.  This process 6 
consisted of the combination of adsorption and microfiltration within a stirred cell 7 
unit for the selective immobilization of β-lactoglobulin and casein derived peptides 8 
(CDP) from whey. The adsorbed proteins were hydrolyzed in-situ which resulted in 9 
the separation of peptide products from the substrate and fractionation of peptides. 10 
Two different hydrolysates were produced: (i) from CDP (IC50 =287μg/mL) and (ii) 11 
from β-lactoglobulin (IC50=128g/mL). IC50 is the concentration of inhibitor needed 12 
to inhibit ACE by half. The well known antihypertensive peptide IPP and several 13 
novel peptides that have structural similarities with reported ACE inhibitory peptides 14 
were identified and characterized in both hydrolysates. Furthermore, the hydrolysates 15 
were assessed for bitterness. No significant difference was found between the control 16 
(milk with no hydrolysate) and hydrolysate samples at different concentrations (at, 17 
below and above the IC50). The IC50 is the concentration of peptide needed to inhibit 18 
ACE by half. 19 
 20 
Keywords: ACE inhibitory peptides, β-lactoglobulin, Casein derived peptides, ion 21 
exchange resin, protease N ‘Amano’, bitterness. 22 
 23 
1.  Introduction 24 
 25 
ACE inhibitory peptides derived from natural sources such as whey proteins could be 26 
used to prevent and help to treat hypertension by dietary intervention. Several animal 27 
model and human trial studies have demonstrated the antihypertensive effect of ACE 28 
inhibitory peptides derived from milk proteins (Abubakara, Saito, Kitazawa, Kawai & 29 
Itoh, 1998). Some fermented milk products and hydrolysates containing ACE 30 
inhibitory peptides from milk proteins are already in the market (Korhonen & 31 
Pihlanto, 2006).   32 
 33 
In recent years, several sequences of bioactive peptides from natural sources including 34 
peptides from β-lactoglobulin and casein derived peptides that can inhibit ACE 35 
activity have been discovered (Jauregi, 2008; Jauregi & Welderufael, 2010; Ortiz-36 
Chao et al., 2009; Pihlanto-Leppala, Koskinen, Piilola, Tupasela & Korhonen, 2000). 37 
ACE, which is a constituent part of the rennin-angiotensin system, is a widely 38 
accepted enzyme and is considered as the first line of therapy to treat hypertension 39 
(Coppey et al, 2006). The first ACE inhibitory peptide was isolated from snake venom 40 
(Ferreira, 1965) and most antihypertensive drugs such as, captopril, lisinopril and 41 
enalapril that can block the ACE mediated production of angiotensin II were designed 42 
based on the snake venom peptide scaffold. The inactivation of ACE also results in 43 
an increase in the nonapeptide bradykinin which is a vasodilator. Because of these 44 
dual vascular and endothelial protective mechanism of ACE inhibition, the production 45 
of nitric oxide is stimulated, vascular smooth muscle is relaxed and fibrinolysis is 46 
increased (Ceconi, Francolini, Olivares, Comini, Bachetti & Ferrari, 2007). 47 
 48 
 49 
ACE has two biologically active substrates: a decapeptide angiotensin I (Asp-Arg-50 
Val-Tyr-Ile-His-Pro-Phe-His-Leu) and a nonapeptide bradykinin (Arg-Pro-Pro-Gly-51 
Phe-Ser-Pro-Phe-Arg). Cheung and co-authors (1980) reported the importance of the 52 
C-terminal sequences of ACE inhibitory peptides by studying the binding of two 53 
peptides Hippuryl-Histidyle-Leucine (Hip-His-Leu) and Hippuryl-Phenylalanine-54 
Arginine (Hip-Phe-Arg) that have similar C-terminal di-peptides with that of 55 
angiotensin I and bradykinin. They reported that these two peptides had similar 56 
binding affinity trends as angiotensin I and bradykinin, hence indicating substrate 57 
specificity of ACE.  58 
 59 
ACE has specificity for smaller peptides up to 12 amino acids in length with 60 
hydrophobic and positively charged amino acids at the C-terminal end (Cheung et al., 61 
1980; Mullally, Meisel & FitzGerald, 1997b; Nakamura, Yamamoto, Sakai, Okubo, 62 
Yamazaki & Takano, 1995). Wu and co-authors (2006) also recently reported the 63 
most favorable structure-function relationship of di- and tri-peptide sequences for 64 
potent ACE inhibition; di-peptides with amino acids with bulky and hydrophobic side 65 
chains are more favorable while tri-peptides with aromatic amino acids at the 66 
carboxyl end, hydrophobic amino acids in the amino terminus and positively charged 67 
in the middle are more favorable. In addition to their amino acid composition and 68 
sequences, peptides have to be able to resist the gastrointestinal digestion in order to 69 
be absorbed and pass to the circulatory system so that they can reach the peripheral 70 
organ in active form and exert its biological effect (Quiro’s, Contreras, Ramos, Amigo 71 
& Recio, 2009).    72 
Several processes have been proposed for the production of hydrolysates with ACE 73 
inhibitory activity based on fermentation and enzymatic hydrolysis of food proteins. 74 
However most of these either produce hydrolysates with complex mixtures of 75 
peptides or use further purification steps for enrichment purposes (see Table 1). We 76 
have developed an integrative process for the production of ACE inhibitory peptides 77 
from β-lactoglobulin and CDP (Welderufael and Jauregi, 2010: Welderufael, Gibson 78 
and Jauregi, 2012). This process has several advantages: it is simple as it avoids 79 
subsequent purification and enrichment steps; less complex hydrolysates are produced 80 
with high potency (i.e., low IC50); using the ion exchanger increases enzyme stability; 81 
it enables enzyme recycling.  Moreover, it is well known that hydrolysis of casein 82 
results in many bitter peptides (Kilara & Panyam, 2003) and often those amino acid 83 
sequences with high bioactivity are responsible for increased bitterness. Especially 84 
hydrophobic peptides with smaller molecular weight, less than 3 kDa, are the reason 85 
for this undesirable taste that hinders their incorporation into food products (Cheung 86 
& Li-Chan, 2010). 87 
 88 
The purpose of the current work was to characterise, identify and evaluate the 89 
structure-function relationship of the major peptides in the hydrolysates produced by 90 
the integrative process. The in-vitro stability of the hydrolysates was assessed by 91 
simulating the gastrointestinal digestion using pepsin and corolase PP. Moreover, the 92 
in silico digestion of the major peptides was carried out with pepsin, trypsin and 93 
chymotrypsin.  Finally the sensory attributes of the hydrolysates in milk drinks were 94 
evaluated at different hydrolysate concentrations at, below and above their IC50. 95 
2. Materials and Methods 96 
 97 
2.1. Materials and reagents 98 
 99 
Bovine β-lactoglobulin, N-Hippuryl – L – Histidyle – L – Leucine (HHL), α-100 
lactalbumin, bovine serum albumin (BSA), hippuric acid (HA), angiotensin 101 
converting enzyme (ACE; EC 3.4.15.1),  bicinchoninic acid solution (BCA), copper-102 
sulphate solution and DEAE sepharose® were purchased from Sigma (Steinhein, 103 
Germany). Flat sheet microfiltration membranes (0.45mm), potassium mono-104 
phosphate, potassium di-phosphate, sodium chloride (NaCl), trifluoroacetic acid 105 
(TFA), acetonitrile, hydrochloric acid, and sodium hydroxide were purchased from 106 
Fisher Scientific UK Limited. Glycerol from BDH laboratory supplies (England). 107 
Food grade sodium mono-phosphate, sodium di-phosphate, sodium chloride (NaCl) 108 
were purchased from Meridian star, United Kingdom. Protease N ‘Amano’ of Bacillus 109 
subtilitis was obtained from Amano Enzyme Inc., Nagoya, Japan (191,000 units = gm) 110 
where one unit of enzyme produces amino acids equivalent to 0.1 gm of tyrosine in 60 111 
min at pH 7 and a temperature of 55 
o
C. The preferred hydrolysis of this enzyme is at 112 
the C-terminus of threonine, cysteine, methionine, phenylalanine and leucine (Ortiz 113 
Chao 2008). Amicon filtration cell was obtained from Amicon a Grace company. 114 
Syringe driven PVDF filter (0.45 µm and 0.2 µm) was obtained from Millipore 115 
Corporation, Bedford, UK. Skimmed milk was obtained from a local retailer and all 116 
other reagents and chemicals were analytical grade.  117 
 118 
2.2. Methods 119 
2.2.1. Whey preparation  120 
 121 
Pasteurised skimmed milk was bought from the local supermarket and heated at 35 
o
C. 122 
Then commercial rennet was added at 0.3 mL/L and stirred gently for 1 min. The milk 123 
was left for 1 h and then the casein coagulum was cut vertically (25 X 25 mm) with a 124 
knife to drain the lactoserum. Incubation was extended for 20 min after which the 125 
whey was scooped from the vessel and filtered using cheese cloth. The collected whey 126 
was stored at -20 
o
C until used for further experiments. 127 
 128 
2.2.2. Hydrolysate production 129 
 130 
Lab scale production of hydrolysates for chemical characterisation 131 
The hydrolysates were produced from β-lactoglobulin and CDP in sweet whey 132 
following an integrative approach as described in our previous work (Welderufael  133 
Gibson and Jauregi 2012).  The integrative process consists of three main unit 134 
operations: (1) ion exchange adsorption (2) hydrolysis and (3) microfiltration. These 135 
unit operations were integrated within a stirred cell (200 ml) fitted with a 136 
microfiltration membrane where 10 mL of ion exchange adsorber were mixed with 137 
100 mL of whey during 10 minutes. The non-adsorbed whey proteins were filtered. 138 
Then selective hydrolysis of the bound proteins (CDP and -lactoglobulin) was 139 
carried out followed by microfiltration of the first hydrolysate product with peptides 140 
mainly from CDP (4
th
 step). Two hydrolysates were produced from CDP, one after 2 141 
hours hydrolysis and the second one after 6 hours hydrolysis (Fig 1). One β-142 
lactoglobulin hydrolysate product was formed by first hydrolysing the bound proteins 143 
for 2 hours, then filtering the resulting hydrolysate and extending the hydrolysis for a 144 
further six hours with fresh enzyme (2+6 h hydrolysis in Figure 1) followed by 145 
microfiltration and recovery of the hydrolysate All hydrolysis reactions were carried 146 
out with Amano N enzyme at pH 7, 45 
o
C and E:S ratio of 1:100 and for the the β-147 
lactoglobulin derived hydrolysate we also investigated the effect of reducing the E:S 148 
ratio to 1:50. At the end of the hydrolysis the hydrolysates were fractionated using 1 149 
kDa ultrafiltration membrane which yield two different hydrolysate products: P1 and 150 
P2 with peptides derived  from CDP. These hydrolysate products were further 151 
fractionated with semi-prep RP-HPLC prior to MS analysis; the hydrolysate derived 152 
from β-lactoglobulin (P3) was less complex hence it was directly injected into the 153 




Scaled up production of hydrolysates for sensory evaluation 158 
The hydrolysate production was scaled up to process 2 L of whey. The process was 159 
the same as that describe above and in Figure 2 but was carried out in the pilot plant 160 
with the larger equipment used for each unit operation. The ion exchange resin (200 161 
mL) and whey (2 L) were mixed for 10 min with continuous stirring (400 rpm at room 162 
temperature) in a stirred tank with a heating water jacket through which water is 163 
circulating (2.5 L, Applicon Biotechnology, Holland) at room temperature. The 164 
mixture was transferred to a feed tank and from there it was pumped into the filtration 165 
unit which consisted of a cross flow filtration system (PCI Midi ultrafiltration Plant, 166 
UK, Whiteley, Fareham) fitted with 0.22 µm nitrocellulose microfiltration membrane 167 
(Millipore Corporation, UK, Watford) by applying a pressure of 100 psi at an average 168 
flow rate of 10 mL/min. The non-adsorbed proteins went through and removed while 169 
the retentate containing the resin, CDP and β-lactoglobulin were recycled back to the 170 
reaction vessel. The hydrolysis process was carried out exactly at the same conditions 171 
as in the lab scale experiments (see above). After 2 hours hydrolysis the mixture was  172 
passed through the cross flow filtration system and the first hydrolysate product 173 
containing mainly CDP derived peptides was collected in the permeate. The retentate 174 
was recycled back to the reaction vessel and hydrolysis was resumed for 6 more hours 175 
(2+6) by adding fresh enzyme at an E:S ratio of 1:50 (as in lab scale process) to 176 




2.2.3. Micro QTOF electrospray ionisation tandem mass spectrometry (ESI 181 
MS/MS) for amino acid sequencing of peptides derived mainly from CDP at 182 
2 h 183 
 184 
The freeze dried hydrolysate fractions were taken up in 100µl of HPLC grade water 185 
and then an aliquot diluted 1:1 in water containing 0.1% formic acid for infusion into 186 
the mass spectrometer. The mass spectrometer used was a Bruker MicroTOFQ II 187 
(Bruker Daltonic, Bremen, Germany) equipped with electrospray ionisation source. 188 
The samples were infused into the source, at 3µL/min, using a Harvard syringe pump 189 
equipped with a 100µL syringe. The mass spectrometer had previously been 190 
calibrated over a mass range of m/z 300-3000 using Agilent Tunemix™. 191 
 As each spectrum appeared a major peptide mass was isolated and fragmented in the 192 
collision cell using sufficient energy to reduce the precursor ions to about 10% and to 193 
produce an intense product ion spectrum. The accurate mass of each precursor ion 194 
was then used to predict a formula to within approximately 20ppm accuracy and that 195 
was used in combination with the MS/MS spectrum to obtain a partial or full amino 196 
acid sequence. Software used was Bruker sequence editor and Mass Analysis Peptide 197 
Sequence Prediction (MAPSP). 198 
 199 
2.2.4. LC-ESI/MS method for peptide identification in β-lactoglobulin hydrolysate  200 
 201 
Peptides of β-lactoglobulin hydrolysate and peptides in sweet whey were analysed by 202 
LC-MS. Samples were reconstituted in HPLC grade water (1:100) and 2 µL injected. 203 
The peptides were separated using reverse phase liquid chromatography (RP-HPLC) 204 
with an Agilent 1100 HPLC system (Agilent Technologies, CA, USA). The column 205 
used was a Nova-Pak C18 column (150 × 2.1 mm i.d.). A gradient solvent system was 206 
applied with eluent “A” as 0.1% formic acid in water and eluent “B” 0.1% formic acid 207 
in acetonitrile. The flow rate was 0.2 mL/min and, the column and the auto sampler 208 
temperature were kept at 25 and 10 
oC respectively. Eluent “A” was 98 to 55% for 45 209 
min, 55 to 30% for 5 min and then kept at 30% for 5 min, 30 to 98% for 5 min and 210 
98% for 15 min. The peaks were identified using a Bruker MicroTof QII high 211 
resolution TOFMS equipped with an electrospray ionisation (ESI) source. The ion 212 
spray voltage was held at 4500V in positive ion mode. The nebuliser gas was nitrogen 213 
at a pressure of 1.0 bar; drying gas and temperature were 8 L/min and 180 
o
C 214 
respectively. The instrument was interfaced to a computer running Bruker Data 215 
Analysis software version 4 and data acquired over a mass range of 50-3000 Da. 216 
2.2.5. Determination of ACE inhibitory activity 217 
The ACE inhibitory activity of hydrolysates was measured following the HPLC based 218 
method by Hyun and Shin (2000) with some modifications as described in 219 
Welderufael and Jauregi (2010). The enzymatic assay in this method was based on the 220 
hydrolysis of the substrate, 5mM HHL in a 0.1M sodium phosphate buffer (pH 8.2) 221 
with 0.3M NaCl by the ACE (60mU) which resulted in the production of hippuric 222 
acid (HA). The hippuric acid was determined by RP-HPLC) as described in 223 
Welderufael and Jauregi (2010) using a Dionex HPLC  system (Camberley, UK) that 224 
consisted of, a P680 HPLC pump, ASI-100 automated sample injector, thermostatted 225 
column compartment TCC-100 and PDA-100 photodiode array detector and a C18 226 
column (Ace5 250 x 4.6 mm).  227 
 228 
The percentage of ACE inhibitory activity (ACEi %) was calculated based on the 229 
hippuric acid liberated in the hydrolysate sample in relation to that in the control 230 
sample (water). 231 
 232 
The IC50 of hydrolysates was determined by making serial dilutions (1/1, 1/2.5, 1/5, 233 
1/10, 1/25 and 1/50) of the hydrolysate and plotting the inverse of their ACEi% versus 234 
the inverse of their total protein concentration. The IC50 was determined from the 235 
resulting linear equation and expressed as µg/mL.  236 
2.2.6. Sensory evaluation 237 
  238 
The sensory evaluation of the products was reviewed and approved by the University 239 
of Reading Ethics Committee. All participants gave written informed consent prior to 240 
taking part in the study. Sensory discrimination tests were carried out for the two 241 
different whey protein hydrolysates: (i) hydrolysate from CDP, and (ii) hydrolysate 242 
from β-lactoglobulin. Prior to the sensory testing, the IC50 values of both hydrolysates 243 
were measured as 145 µg/mL for β-lactoglobulin derived hydrolysate and 288 µg/mL 244 
for CDP derived hydrolysate. The hydrolysates were spray dried and incorporated into 245 
pasteurised semi skimmed milk based at three different concentrations related to their 246 
IC50: 100, 150 and 200 µg/mL for the β-lactoglobulin derived hydrolysate and 200, 247 
300 and 400 µg/mL for the CDP derived hydrolysate. Samples were then stored at 248 
4 °C for 24 h. Volunteers (n=39, untrained, age 18-60) were recruited from the 249 
students and staff of the University of Reading. The sensory tests were carried out in 250 
individual sensory booths under artificial daylight conditions. Samples (10 mL) were 251 
coded with three-digit random number and held in plastic cups (30 mL). The 252 
discrimination test followed a forced choice triangle test methodology, each panellist 253 
receiving a triad of either two samples and a control (milk without hydrolysate) or 254 
vice versa, sample presentation orders were balanced. Panellists were asked to move 255 
the sample around the mouth and then expectorate. They were asked to select the 256 
sample that was different out of the three and to describe the difference(s) perceived. 257 
Water and crackers were used for palate cleansing in between the samples.  258 
2.2.7. Stability study 259 
 260 
2.2.7.1. Gastrointestinal digestibility study 261 
 262 
The in-vitro stability of hydrolysates was studied by simulating the gastrointestinal 263 
environment and subjecting them to the action of pepsin at pH 2 and E: S ratio of 1: 264 
50, temperature 37 
o
C for 90 min as previously described by Ortiz-Chao (2008). After 265 
this incubation, the hydrolysate was adjusted to pH 7 and the hydrolysis was started 266 
by adding corolase PP at E/S ratio of 1:25 for 150 min in a water bath with shaking. 267 
The reaction mixture was stopped by heating at 95 
o
C for 15 min and then centrifuged 268 
for half an hour at 15000 x g. Finally the supernatant was stored in the freezer at  269 
– 20 oC until further analysis. 270 
 271 
2.2.7.2. In-silico digestibility study 272 
 273 
In silico digestion of the peptides identified in this work was performed using a 274 
combination of pepsin, trypsin and α-chymotrypsin to simulate in-vitro human 275 
gastrointestinal digestion with the software PeptideCutter proteomics tool 276 
(http://www.expasy.org). The preferred hydrolysis sites of these three gastrointestinal 277 
digestive enzymes are:  N- and C-terminus of phenylalanine, tyrosine, tryptophan and 278 
leucine for pepsin; C-terminus of arginine and lysine for trypsin; and C-terminus of 279 
tryptophan, tyrosine, phenylalanine, leucine, methionine and histidine for α-280 
chymotrypsin.  281 
 282 
2.2.7.3.  Prediction of ACE inhibitory activity of main peptides in hydrolysates and 283 
their in silico digests 284 
 285 
The ACE inhibitory activity of main peptides identified in the hydrolysate fractions 286 
was predicted using BIOPEP software 287 
(http://www.uwm.edu.pl/biochemia/index_en.php) and also published works. 288 
Furthermore using the same software the ACE inhibitory activity of the in-silico 289 
digested peptide fragments was predicted  290 
 291 
2.2.8. Total protein analysis  292 
The total protein content of hydrolysates was determined based on the bicinchoninic 293 
acid (BCA) assay. In brief, two ml of the BCA working reagent (copper sulphate 294 
solution: BCA solution at a ratio of 1:50) were mixed with 100 µl of sample. The 295 
mixture was incubated for 30 min at 37 
o
C and the absorbance reading was taken at 296 
562 nm using ultrospec 1100 pro UV/ visible spectrophotometer. Serial dilutions of 297 
bovine serum albumin were used as standard.   298 
 299 
 300 
2.2.9. Statistical analysis 301 
The analysis of variance for the results of the above experiments was computed using 302 
Genstat statistical software package for statistical comparison among groups of 303 
different treatments, with P<0.05 indicating significant difference. All the above 304 
results were expressed as Mean ± standard error of mean (S.E.M). Data from the 305 
sensory analysis was analyzed using the binomial probability model at a significant 306 
level of 0.05 (Difftest version 2.0, 2002, www.difftest.co.uk). 307 
 308 
3. Results and discussion 309 
 310 
 311 
Mass spectrometry analysis of peptide compositions in sweet whey confirmed the 312 
presence of ten peptides ranging from 1881.1 to 20978.7 Da (see Figure 2). Several 313 
studies also indicated the presence of CDP in whey during cheese manufacturing as a 314 
result of proteolysis of casein proteins by chymosin and endogenous milk enzymes 315 
(Fox, 1993). Particularly, plasmin activity could be high at conditions of rennet whey 316 
preparation (35±2 
o
C and pH of milk) (Bastian and Brown, 1996).  317 
 318 
 319 
In our previous works (Welderufael and Jauregi, 2010 and Welderufael et al 2012) we 320 
demonstrated that applying the integrative approach to whey resulted in the 321 
production of two different hydrolysates, one from CDP and the other one from -322 
lactoglobulin. In the present work we carried out the chemical characterisation of each 323 
hydrolysate using mass spectrometer techniques in order to identify the main peptides 324 
contributing to the ACE inhibitory activity measured in these hydrolysates.  325 
 326 
3.1. Identification and characterisation of major peptide composition derived from 327 
active fractions of CDP 328 
The structure-function relationship of ACE inhibitory peptides is not fully 329 
characterised however some information exists and quantitative structure activity 330 
relationships (QSAR) have been established (Pripp, Isaksson, Stepaniak, Sørhaug,&  331 
Ardö, 2005 and Wu, Aluko, & Nakai, 2006) which, enable prediction of ACE 332 
inhibitory activity from a knowledge of amino acid sequences.  ACE cleaves di-333 
peptides from the C-terminal sequences of peptide substrates and particularly the three 334 
amino acids from the C-terminal are very important for their binding to ACE (Lopez-335 
Fandino et al., 2006). Furthermore, this enzyme prefers small peptides up to 12 amino 336 
acids in length with hydrophobic amino acids (aromatic: phenylalanine, tryptophan 337 
and tyrosine; and branched chain amino acids: valine, leucine and isoleucine) in one 338 
of the three sequences of the C-terminal (Cheung et al., 1080; Mullally et al., 1997b). 339 
The positively charged amino acids such as arginine and lysine at the C-terminal 340 
sequences were also reported to contribute towards ACE inhibitory or 341 
antihypertensive effect (Cheung et al., 1980).  342 
 343 
The mass spectrometry analysis of the 2 and 6 h hydrolysates which had permeated 344 
through the 1kDa ultrafiltration membrane show that both hydrolysates contain almost 345 
the same peptide composition with peptides mainly from casein derived peptides (see 346 
Table 2 for peptide compositon of the 2 h hydrolysate). 347 
 348 
 349 
These two hydrolysates were fractionated into 8 fractions (see 2 h hydrolysate 350 
chromatogram in Fig 3 ) and the three polar fractions A, B and C showed the highest 351 
bioactivity. Particularly, fraction “B” in both, the 2 (see Table 2 and Figure 4) and 6 h 352 
hydrolysates (data not shown) contained IPP. This peptide has been identified as the 353 
most potent ACE inhibitor from milk protein and it is derived from casein with an 354 
IC50 of 5µM (1.6 µg/mL) (Nakamura et al., 1995). In recent years, several human 355 
trials and animal studies have demonstrated the antihypertensive activity of this 356 
tripeptide (Ehlers,  Nurmi, Turpeinen, Korpela, & Vapaatalo, 2011). In addition, this 357 
fraction, in both hydrolysates, contained the peptide His-Leu-Pro (HLP) which could 358 
be a contributor to ACE inhibitory activity as it is a fragment of the β-casein derived 359 
hexapeptide Leu-His-Leu-Pro-Leu-Pro (LHLPLP). This hexapeptide has been 360 
reported to have an IC50 = 5.5 ± 0.5 µM = 3.8 µg/mL and has also shown a significant 361 
blood pressure reduction effect at a dosage of 2 mg/kg (Quiros et al., 2009).  362 
 363 
Fraction “C” of the 2 h hydrolysate contained a β-lactoglobulin derived peptide Leu-364 
Asp-Ile-Gln-Lys (LDIQK) while it was absent in the 6 h one. This pentapeptide is a 365 
fraction of the ACE inhibitory hexapeptide Gly-Leu-Asp-Ile-Gln-Lys (GLDIQK) 366 
which has been reported as a potent ACE inhibitor with an IC50 of 27.5 μM or 18.5 367 
µg/mL (Schlothauer, Schollum, Singh & Reid, 1999). This same fraction, in both 368 
hydrolysates, also contained an octapeptide Gln-Asp-Lys-Thr-Glu-Ile-Pro-Thr 369 
(QDKTEIPT). In order to identify the main peptides responsible for the high 370 
bioactivity of fraction C, the fraction of the 6 h hydrolysate was further fractionated 371 
into four sub-fractions. This led to a fraction containing almost solely the octapeptide 372 
QDKTEIPT and its IC50 was 17.5 μg/mL (see Figure 5 and 6). So this proves that the 373 
octapeptide was one of the main contributors to the IC50 measured in fraction C (113 374 
g/ml). Furthermore this peptide holds some structural similarities to other reported 375 
ACE inhibitory peptides. Quirós et al. (2005) reported an ACE inhibitory peptide 376 
Leu-Val-Tyr-Pro-Phe-Thr-Gly-Pro-Ile-Pro-Asn (LVYPFTGPIPN) from caprine kefir 377 
with an IC50 of 27.9 ± 2.3 μg/mL. This peptide has the same two penultimate 378 
sequences Iso-leucine and Proline at the end of the C-terminal as the octapeptide 379 
(QDKTEIPT). Moreover both peptides have uncharged and polar amino acids such as, 380 
asparagine and threonine at the C-terminal end. Therefore, taking into account all the 381 
above evidence both peptides LDIQK and QDKTEIPT are most likely to be the main 382 
contributors to the high potency of fraction “C” of the 2 h hydrolysate. The 383 
octapeptide QDKTEIPT is the main contributor to the potency of the 6 h hydrolysate.  384 
 385 
The β-lactoglobulin derived tetrapeptide Lys-Ile-Pro-Ala (KIPA) in fraction “B” has a 386 
very similar peptide sequence to a tripeptide reported by  Abubakar and co-authors 387 
(1998), the  Ile-Pro-Ala (IPA), which was found to be a potent ACE inhibitor with 388 
IC50 = 141 µM (42 g/mL). 389 
 390 
Fraction “A” also showed a high ACEi activity. Six peptide sequences Leu-Arg, Met-391 
Ala-Pro-Lys, Ala- Met-Ala-Pro-Lys, Ile/Leu-Gln-Lys, Val-Ser-Lys and Thr-Val-Lys 392 
were among the peptides identified in this fraction (see Figure 7). These peptides, like 393 
the other well characterised ACE inhibitory peptides, also had some structural 394 
features of ACE-inhibitors, e.g: the presence of charged followed by hydrophobic 395 
amino acid residues in one of the penultimate sequences at the C-terminal sequences.  396 
Interestingly, the tripeptide Thr-Val-Lys found in this fraction contained the same C-397 
terminal sequence as the ACE inhibitory peptide Val-Lys extracted from 398 
buckwheat with an IC50 value of 13µM = 3.17 µg/mL (Vermeirssen, Bent, Camp, 399 
Amerongen & Verstraete, 2004).  400 
 401 
 402 
3.2.  Identification and characterization of major peptides in the hydrolysate 403 
containing peptides  derived from β-lactoglobulin 404 
 405 
Selective hydrolysis of the immobilised β-lactoglobulin after removing the 2 h 406 
hydrolysates of casein derived peptides by adding two different concentrations of 407 
fresh enzyme at an E:S ratio of 1:100 and 1:50 resulted in a hydrolysate with a 408 
composition different to that obtained at 2 h, with peptides mainly from β-409 
lactoglobulin and with increased bioactivity. Even if the peptide composition of these 410 
two β-lactoglobulin derived hydrolysates was similar, the relative abundance of 411 
individual peptides was different (see Figure 8a and b).  Almost all these major 412 
peptides contained either charged or hydrophobic amino acids in one of the three C-413 
terminal sequences (see Table 3). 414 
 415 
Interestingly, the relative abundance of the tetrapeptide Ile-Ile-Ala-Glu (IIAE) 416 
increased with an increase in an E: S ratio from 1:100 to 1:50. This peptide was one of 417 
the two most abundant peptides in the hydrolysate of the 1:50 E:S ratio and shared 418 
similarities with a potent microalgae derived tripeptide Ile-Ala-Glu (IAE). This 419 
tripeptide was reported to have an IC50 = 34.7μM = 11.5μg/mL (Suetsuna & Chen, 420 
2001). The other major peptide was Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-Leu-421 
Leu (KPTPEGDLEILL) and it increased with an increase in E:S ratio (see Figure 8a 422 
and 8b) which resulted in an increase in ACE inhibitory activity. This peptide 423 
contained three hydrophobic amino acids at the end of the C-terminal sequence. 424 
Therefore these two peptides IIAE and KPTPEGDLEILL could be the major 425 
contributors for the high ACE inhibitory activity measured in this hydrolysate. 426 
Furthermore the two amino acids at the N-terminal sequence of KPTPEGDLEILL 427 
were similar to the dipeptide Lys-Pro (KP) that was isolated from anchovy and bonito. 428 
This dipeptide is known for its high ACE inhibitory activity, IC50= 22 µM = 429 
5.3μg/mL and an animal study showed a significant blood pressure reduction effect 430 
(Toshiaki, Jianen, Duong & Susumu, 2003). A tripeptide Val-Phe-Lys (VFK) was 431 
also identified in this hydrolysate and it has been reported to have ACE inhibitory 432 
activity with IC50 = 1029 µM = 402.6 µg/mL (Pihlanto-Leppala et al., 2000).   433 
 434 
Peptides IVTQ, VAGT, LDAQ, RL, IIAE, VFK LIVTQ and FK were also identified 435 
in the hydrolysate of a standard β-lactoglobulin solution (not immobilized) obtained 436 
at the same experimental conditions in previously carried out work by our group 437 
(Ortiz-Chao et al., 2009). Out of these eight peptides, all except LIVTQ were 438 
identified in the mixtures of the most active fractions. Therefore the hydrolysis 439 
process shows good reproducibility. An additional novel peptide KPTPEGDLEILL 440 
was identified in the current work that could be a potential contributor to ACE 441 
inhibitory activity. Besides these interesting findings, the most interesting outcome of 442 
this work is that unlike the complex peptide mixture produced from the standard β-443 
lactoglobulin solution, the hydrolysates produced here were less complex and with 444 
comparable IC50 values (IC50= 128 µg/mL for the immobilized whey whereas 102 445 
μg/mL for the standard β-lactoglobulin solution).  446 
 447 
3.3. Impact of simulated gastrointestinal digestion on ACE inhibitory activity 448 
 449 
Some food protein derived ACE inhibitory peptides may lose some of their ACE 450 
inhibitory activity after oral administration due to further hydrolysis by 451 
gastrointestinal enzymes (Walsh et al., 2004). In this work, the ACE inhibitory 452 
activity of CDP and β-lactoglobulin derived hydrolysates was further assessed after 453 
the in-vitro simulated gastrointestinal digestion. The results showed no significant 454 
differences in ACE inhibitory activity before and after the in-vitro digestion (see 455 
Figure 9). This could be because either the potent peptides that contributed to the 456 
inhibitory activity might be resistant to digestion or the digestion resulted in partial 457 
hydrolysis and the active sequences were maintained intact with little impact on the 458 
bioactivity.  This was tested further by carrying out in-silico digestion of major 459 
peptides in most active fractions. 460 
 461 
3.4. In-silico  digestibility study of CDP derived peptides 462 
 463 
 464 
In order to assess the digestibility of specific peptides present in the hydrolysates, in-465 
silico digestion of individual peptides was carried out following the method in section 466 
2.2.7.2. Furthermore the ACE inhibitory activity of the peptides produced after 467 
digestion was predicted following method in 2.2.7.3. Out of 25 peptide sequences 468 
reported in the 2 h hydrolysate, 9 of the peptides were found to be resistant to 469 
digestive enzymes including the most potent ACE inhibitory tripeptide IPP while only 470 
4 were completely digested. Twelve peptides were partially hydrolysed (see Table 4) 471 
but their C-terminal sequences remained intact. Furthermore, out of the ten peptides 472 
that were mainly derived from β-lactoglobulin, only two were completely digested, 473 
three were resistant to gastrointestinal digestion while five of the peptides were 474 
partially hydrolysed. The three peptides resistant to the digestive enzymes were: Ile-475 
Ile-Ala-Glu, Ile-Val-Thr-Gln and Val-Ala-Gln-Thr (see Table 3).  476 
 477 
The octa-peptide Gln-Asp-Lys-Thr-Glu-Ile-Pro-Thr that was predominant in the 478 
active fraction “Fraction C” (Table 2 and table 4) was digested into two peptides Gln-479 
Asp-Lys and Thr-Glu-Ile-Pro-Thr. These two digests have some structural features of 480 
ACE inhibitors. Both peptides contained charged or hydrophobic amino acids at the 481 
two penultimate sequences at the end of the C-terminal.   482 
 483 
A peptide Leu-Thr-Gln-Thr-Pro-Val (LTQTPV) was predicted to loose L-leucine 484 
from the N-terminal sequence and produce TQTPV. This peptide shared similarities at 485 
the C-terminal sequence with an ACE inhibitory peptide Asn-Ile-Pro-Pro-Leu-Thr-486 
Gln-Thr-Pro-Val produced from fermented milk by Lactobacillus delbrueckii 487 
subspecies bulgaricus SS1 and Lactobacillus lactis subspecies cremoris FT4 with an 488 
IC50 of 173 µM (Gobbetti, Ferranti, Smacchi, Goffredi & Addeo, 2000).  489 
 490 
The octapeptide derived from caseinomacropeptide Met-Ala-Ile-Pro-Pro-Lys-Lys-Asn 491 
(MAIPPKKN) was predicted to loose the amino acid asparagine from the C-terminal 492 
sequence resulting in MAIPPKK which is known for its vasodilatory effect. This 493 
peptide is a modest ACE inhibitor with IC50 of 4785μM however, in an animal study 494 
this peptide showed a significant blood pressure reduction effect at a dose level of 495 
10mg/kg (Miguel, Manso, López-fandiño, Alonso & Salaices, 2007).   496 
 497 
The peptide Ile-Ile-Ala-Glu-Lys-Thr (IIAEKT) was susceptible to partial digestion 498 
and was predicted to loose threonine from the end of the Carboxyl-terminal. This 499 
fragment, IIAEK (lactostatin) was reported to exhibit a greater hypercholesterolemia 500 
effect even when compared to the drug β-sitosterol as tested in rats (Nagaoka et al., 501 
2001). 502 
 503 
Interestingly the findings from the in-vitro and in-silico digestibility studies were in 504 
agreement as using both methods it was found that digestion of the hydrolysates 505 
resulted in no loss of ACE inhibitory activity.  506 
3.5. Sensory evaluation 507 
 Sensory is one of the most important aspects that need to be given consideration after 508 
the production of hydrolysates. The release of bitter tasting peptides can significantly 509 
affect the sensory attributes of the resultant hydrolysate and subsequently alter the 510 
quality of products to which they are added. Therefore to assess whether the  511 
hydrolysate products developed in this study had any effect on a typical beverage, 512 
they were added into milk which was subjected to a sensory discrimination test. Milk 513 








  522 
Overall, for the CDP and β-lactoglobulin derived hydrolysates no significant 523 
differences were found in perception between any of the three samples and the control 524 
milk samples (see tables 5 and 6). However the sample with the lowest level of 525 
hydrolysate was the most different to the control milk (p=0.066). With the relatively 526 
low number of assessors (n=39) used in the trials, although there was no significant 527 
differences in perception found, the samples could not be declared with confidence to 528 
be perceptually identical, as either the proportion of discriminators amongst the 529 
population was too high (>30%), or at a risk level of 10 % (type II error) the 530 
probability of correctly identifying a sample from the control in any individual trial 531 
was too high (the upper bound limit), or the probability of obtaining a result higher 532 
than the upper bound limit was too high. The results of this pilot study must be scaled 533 
up and taken to a larger consumer trial in order to prove the samples with hydrolysate 534 
are perceptually identical to milk.  535 
CDP derived hydrolysates: Three different concentrations of hydrolysate derived 536 
from CDP were tested for sensory attributes. The IC50 of CDP derived hydrolysate 537 
was 288 µg/mL. Therefore we used three different concentrations, (i) 200 µg/mL (ii)  538 
300 µg/mLand (ii) 400 µg/mL.  539 
Although there was no statistical significant difference between the control and the 540 
three different hydrolysate concentrations (see Table 5), comments given by the 541 
assessors were compiled. The 200 µg/mL and the 300 µg/mL were described as less 542 
sweet compared to the control, by 4 and 3 assessors respectively, and 3 assessors 543 
described the taste and odour of the 400 µg/mL as less milky. However, there were no 544 
comments concerning off notes, taints or bitter taste. These findings are very 545 
interesting as they help to demonstrate the advantage of the integrative process in 546 
thatthe hydrolysates produced here are enriched in specific peptides and partially 547 
fractionated which might have resulted in the removal of bitter fractions. Other 548 
authors have used ion exchange as a debittering method (Cheison, Wang & Xu, 549 
2007). Bitterness of hydrolysates is mainly caused by the composition of amino acids 550 
in the peptide sequence.  Smaller peptides less than 3 kDa and hydrophobic amino 551 
acids in the order of phenylalanine (F) ≈ tryptophan (W) > Proline (P) > isoleucine (I) 552 
≈ tyrosine (Y) ≈ histidine (H) are reported to be the main contributors to  bitterness 553 
(Cheung et al., 2010; Linde, Junior, Faria, Colauto, Moraes & Zanin, 2009). In our 554 
hydrolysate, we have identified twenty five peptides from the active fractions that 555 
were permeated through the 1kDa ultrafiltration membrane. Out of the twenty five 556 
major peptides, only four peptides VSK, TVK, VQVT and TVQVT were free from 557 
the above mentioned bitterness causing amino acids. The other twenty one peptides 558 
contain at least one of these amino acids. However even if the majority of these 559 
peptides contained Phe, Tyr, Trp, Pro, Ile or His amino acids,  their position in the 560 
peptide sequence plays a major role in the development of  bitterness as reported by 561 
Otagiri et al. (1985). Otagiri and co-authors reported the above mentioned amino 562 
acids should be at the end of the C- terminal sequences. However, within our 563 
hydrolysate only four peptides PP, IPP, HLP and LTQTP have this structural feature 564 
while the rest contain those amino acids either at the N-terminus or within the peptide 565 
sequence. Furthermore, they found that peptides with arginine followed by proline 566 
had a strong bitter taste.  567 
 568 
β-lactoglobulin derived hydrolysate: Three different concentrations were also tested 569 
for the β-lactoglobulin derived hydrolysate. The IC50 of this hydrolysate was 145 570 
µg/mL. Therefore three different concentrations were chosen in relation to its IC50; (i) 571 
100 µg/mL, (ii) 150 µg/mL (iii) 200 µg/mL. The result showed statistically no 572 
significant difference between the three different concentrations and the control (see 573 
Table 6). From the compiled comments, only 2 assessors out of 39 reported adverse 574 
tastes; one reported sour for the 100 µg/mL sample and the other reported bitter for 575 
the 150 µg/mL.  Moreover, only 4 assessors described the 300 µg/mL samples as less 576 
sweet compared to the control. 577 
  578 
A total of ten major peptides were identified in this hydrolysate and out of the ten 579 
peptides, only three peptides VAGT, RL and LDAQ were free from the above 580 
bitterness causing amino acids. The other seven peptides FK, IIAE, IVTQ, 581 
KPTPEGDLEILL, LIVT, LIVTQ and VFK contain at least one of these bitterness 582 
causing amino acids (F ≈ W > P > I ≈ Y ≈ H). All the identified peptides did not 583 
contain these amino acids at their ultimate C-terminal position. However only three 584 
peptides FK, IIAE and IVTQ contain phenylalanine and isoleucine at the ultimate N-585 
terminus and four peptides KPTPEGDLEILL, LIVT, LIVTQ and VFK contained 586 
proline, isoleucine or phenylalanine within their sequences. Therefore, the majority of 587 
the peptides identified in the hydrolysate according to their chemical structure were 588 
expected not to be bitter which is in agreement with the results of the sensory analysis.  589 
 590 
4. Conclusions 591 
 592 
This study demonstrated that the production process applied in this work resulted in 593 
hydrolysates of high ACE inhibitory activity. The fractionation of hydrolysates by 594 
preparative HPLC and the use of MS techniques helped to identify major bioactive 595 
peptides. This together with available structure activity relationship data including 596 
QSAR enable identification of main peptides contributing to the ACE inhibitory 597 
activity of hydrolysates.  Among these potent peptides some novel sequences were 598 
identified such as, VSK, IIAE, QDKTEIPT, KPTPEGDLEILL and LDIQK . Also the 599 
well known ACE inhibitory peptide IPP was identified in the CDP derived 600 
hydrolysates. The in-vitro simulated gastrointestinal digestibility study showed that 601 
there was no significant change in the ACE inhibitory activity of the hydrolysates 602 
This was also in agreement with the findings from the in-silico digestion study. The 603 
in-silico digestion of both hydrolysates predicted that most of the peptides were either 604 
resistant or only susceptible to partial hydrolysis and the resulting fragments were 605 
predicted to be ACE inhibitory. Hence, no overall loss of ACE inhibitory activity was 606 
predicted. The sensory evaluation of the hydrolysates showed no significant 607 
difference between the reconstituted hydrolysate products and the control. This might 608 
be due to low structural similarity of the peptides with that of bitterness causing 609 
peptides. Overall this work demonstrates the advantage of producing hydrolysates 610 
following the integrative approach as less complex hydrolysates with high potency 611 
and with positive sensory attributes can be produced. 612 
 613 
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Figure 1: Flowchart of production of ACE inhibitory peptides from CDP and β-812 
lactoglobulin (β-Lg). Where P1 and P2 were the permeates of hydrolysates produced 813 
from CDP after 2 and 6 hours hydrolysis and P3 the hydrolysate from  814 
β-lactoglobulin after 2+6 h hydrolysis; P1 and P2 contained mainly CDP derived 815 
peptides and  P3 β-lactoglobulin derived peptides. 816 
 817 
Figure 2: Total ion current (TIC) of sweet whey extract with masses of peaks 818 
analysed by liquid chromatography coupled to mass spectrometry (LCMS). 819 
 820 
Figure 3: Peptide peak profiles of the 2 h hydrolysate permeated through the 1kDa 821 
ultrafiltration membrane (P1) and peak profiles of the 8 fractions using semi-prep RP-822 
HPLC 823 
 824 
Figure 4: (a) MS/MS spectrum of fraction “B” of the 2 h hydrolysate after filtration 825 
through the 1kDa ultrafiltration membrane (P1)  (b) MS-MS spectrum of ion m/z 826 
326.2074 of IPP.  827 
Figure 5: MS/MS spectrum of fraction “C” of the 2 h hydrolysate after filtration 828 
through the 1kDa ultrafiltration membrane (P1). 829 
 830 
Figure 6. MS/MS spectrum of subfraction from fraction“C” of the 6 h hydrolysate 831 
(P2). The spectrum shows the ion m/z 931.4827 which corresponds to the doubly 832 
charged ion of the octapeptide QDKTEIPT (466.2418). 833 
 834 
Figure 7: Micro-TOF/ESI-MS spectrometry of fraction “A” of the 2 h immobilised 835 
whey hydrolysate after filtration through the 1kDa ultrafiltration membrane (P1). 836 
 837 
Figure 8: Base peak chromatograms of hydrolysate with β-lactoglobulin derived 838 




Figure 9: Percentage of ACE inhibitory activity of hydrolysates before and after the 843 
in-vitro digestion using gastrointestinal digestive enzymes (pepsin, corolase PP). 844 
Where 2+6 (E:S=1:100), 2+6 (E:S=1:50) and 2+6 (E:S=1:25) are  hydrolysates 845 
produced after filtering the 2 h hydrolysate (hydrolysate mainly from CDP) and 846 
extending the hydrolysis of β-lactoglobulin for further 6 hours at an E:S ratio of 1:100, 847 




Different ACE inhibitory hydrolysate production methods from whey proteins and from other 
natural sources and their IC50 values. 
 
Methods of production Protein source 
Hydrolysis 
time (hrs) Enrichment  
IC50 
(µg/ml) Reference 
TCA precipitation then 
hydrolysis  Ovine β-lactoglobulin       24 Nil 117-278 (Hernandez-Ledesma et al, 2002) 
          from acid whey     
  Ovine β-lactoglobulin         24 Nil 38-296 (Hernández-Ledesma, Recio, Ramos & Amigo, 2002) 
          from sweet whey     
  Caprine β-lactoglobulin 24 Nil 118-388 (Hernandez-Ledesma et al, 2002) 
          from sweet whey     
Batch  WPC 4 Ultrafiltration (1kDa) 201 (Mullally, Meisel & FitzGerald, 1997a) 
  β-lactoglobulin 4 Ultrafiltration (1kDa) 160 (Mullally et al., 1997a) 
Batch  CMP 3 Nil 477 (Otte, Shalaby, Zakora, Pripp & El-Shabrawy, 2007) 
Fermentation  Milk 24-48 Nil 420-520 (Pihlanto, Virtanen & Korhonen, 2010) 
Immobilized enzyme  Brassica carinata - Nil 338 (Pedroche et al., 2007) 
Fermentation  Blue mussels 6 months Filtered, desalted         1010 (Je, Park, Byun, Jung & Kim, 2005) 
   electrodialised then    
   lyophilized   
Our work (Integrative 
approach)  CDP  2 Nil 287 (Welderufael et al., 2011) 
   Ultrafiltration (1kDa) 67 (Welderufael & Jauregi, 2010) 
  β-lactoglobulin 8 Nil 128 (Welderufael et al., 2011) 
Table 2 
IC50 (µg/mL) value and the major peptides of the three active fractions of the 2 h 
hydrolysate that were permeated through the 1kDa ultrafiltration membrane followed 
by fractionation using semi-prep RP-HPLC. 
 
Fraction Peptides Protein Observed IC50 
    Source Masses (Da)  (µg/mL) 
A PE  245.1057 213 
 L/IK β-Lg 260.1928  
 L/IR β-Lg 288.3398  
 VSK β-casein 333.3596  
 TVK Casein kinase 347.3637  
 PHL k-casein 365.2534  
 I/LQK β-Lg 388.2582  
 MAPK β-casein 446.5118  
 LQPE β-casein 486.2502  
  AMAPK β-casein 517.4536   
B PP k-casein 213.3244 62 
 IPP k-casein 326.2074  
 HLP β-casein 366.3774  
 VFK β-Lg 393.5045  
 KIPA β-Lg 428.5043  
 VQVT k-casein 446.2622  
 LQPE β-casein 486.2572  
 TVQVT k-casein 547.3091  
 LTQTP β-casein 559.3091  
 IASGEPT k-casein 674.7145  
  MAIPPKKN k-casein 449.7635
+2
 (898.5197)   
C MAIPPKKN k-casein 449.7635
+2
 (898.5197) 113 
 QDKTEIPT k-casein 466.2745
+2
 (931.4801)  
 LIVTQ β-Lg 573.3596  
 LTQTPV β-casein 658.3603  





Major peptides identified in hydrolysates produced from β-lactoglobulin after filtering 
the 2 h hydrolysate and extending the hydrolysis for 6 more hours by adding fresh 
enzyme (P3). Where: ** stands for peptides that was commonly found at 2+6 h 
(E:S=1:50) and 2+6 h (E:S = 1:100) and ↓chymotrypsin, ↑pepsin, →Trypsin digesting 
sites of the peptides. 
 
E: S ratio Theoretical pepsin,  Protein  In silico  Molecular Isoelectric 
 trypsin & chymotrypsin  Source predicted ACE  weight point 
  Cleavage site 
  
 inhibitors (Da)a 
(Pi)a 
1: 50 F↓↑K/K↑→F β-LG   294.188 8.75 
 IIAE** β-LG IA, IAE 445.2656 4.6 
 IVTQ** β-LG TQ 460.2766 5.52 
 L↓↑DAQ β-LG DA 446.2245 3.8 
 L↓↑IVT** β-LG  445.302 5.52 
 L↓↑IVTQ** β-LG TQ 573.3606 5.52 
 R→L/L↓R** β-LG RL 288.203 9.75 
 VAGT** β-LG AG, GT 347.1925 5.49 









1: 100 IIAEK→T β-LG IA, IAE, EK 674.4083 6 
a
 is the isoelectric point of peptides from ExPASy proteomics tool and applied only 





In silico digestion of the major peptides identified in the active fraction of the 2 h and 
6 h hydrolysate permeated through the 1kDa ultrafiltration membrane (P1 and P2). 
Where: * stands for peptides that were common to both hydrolysates at 2 and 6 h and 
↓chymotrypsin, ↑pepsin, →Trypsin are cleavage sites of these enzymes. 
 
Hydrolysate Theoretical pepsin, trypsin & In silico predicted Molecular Pia 
(h) chymotrypsin Cleavage site  ACE inhibitors
b Weight (Da)a 
 
2 
 AM↓APK AP 517.2803 
8.80 




GEP, IA, GE,  
SG, GEP, PT 674.3355 
4.00 
 IPP* IPP, IP, PP 326.2074 5.52 
 L↓↑K/I→K*  260.1968 8.75 
 I→QK/L↓↑QK* QK, LQ 388.2554 8.75 
 K→IPA*  IPA, IP 428.2867 8.75 
 L↓↑DIQK* LDIQK, QK 616.3664 5.84 
 L↓↑IVTQ TQ 573.3606 5.52 
 L ↓QPE* LQP, LQ 486.2558 4.60 
 L↓↑R*/R→L* RL 288.2030 9.75 
 L↓TQTP* TQ 559.3086 5.52 




IPP, AIP, PK, IP, 
 PPK, AIPP, PP, AI 896.5179 
10.0 
 M↓APK* AP 446.2431 8.50 
 PE*  245.1132 4.6 
 PH ↓L* HL, PH 366.2136 7.17 
 PP PP 213.1233  
 QDK→TEIPT* IP, EI, TE, PT 931.4731 4.37 
 TVK* VK 347.1925 5.19 
 TVQVT*  547.3086 5.19 
 V↓F↓↑K VF, VFK 393.2496 8.72 
 VSK*  333.2132 8.72 
 VTST VTSTAV 407.2136 5.49 
 VQVT*  446.2609 5.49 
6 EK→VT EK 476.2715 6.10 
E: S=1:100 F↓↑→AQT  466.2296 5.52 
 IIAEK→T IA, IAE,  EK 674.4083 6.00 
 K→VK→E VK, KE 503.3187 8.59 
 SL↑PQN PQ 558.2882 5.24 
a
 Molecular weight and  isoelectric points of peptides (before digestion) taken from 
ExPASy proteomics tool . 
b





Sensory discrimination of CDP derived hydrolysate; where CDP200, CDP300 and 
CDP400 were hydrolysates of casein derived peptides at 200 µg/mL, 300 µg/mL and 































CDP200 39 18 0.066 0.406 0.604 0.033 
CDP300 39 13 0.56 0.215 0.477 0.425 
CDP400 39 13 0.56 0.215 0.477 0.425 
       
a
 Type I error : risk of finding a false difference 
b 
The maximum acceptable proportion of the population that can distinguish between 
the samples (typically an acceptable maximum set at 0.3 or 30 %) 
c
The upper bound is the probability of a correct trial  
d
 The probability of obtaining a higher upper bound value in 39 trials (i.e. of obtaining 








Sensory discrimination of β-lactoglobulin derived hydrolysate; where β-LG100, β-
LG150 and β-LG200 were 100 µg/mL, 150 µg/mL and 200 µg/mL respectively. N is 
number of panellists. 
 
a
 Type I error : risk of finding a false difference 
b 
The maximum acceptable proportion of the population that can distinguish between 
the samples (typically an acceptable maximum set at 0.3 or 30 %) 
c
The upper bound is the probability of a correct trial  
d
 The probability of obtaining a higher upper bound value in 39 trials (ie of obtaining 

































β-LG100 39 10 0.885 0.094 0.396 0.80 
β-LG150 39 16 0.196 0.332 0.555 0.118 
β-LG200 39 17 0.118 0.369 0.579 0.066 
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